Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/071267external-prioritypatent/WO2014081944A2/en
Application filed by Janssen Biotech IncfiledCriticalJanssen Biotech Inc
Publication of CR20150249ApublicationCriticalpatent/CR20150249A/en
Se describe molécula monoespecificas y biespecificas que contienen el dominio de FN3 de EGFR y/o c-Met, nucleótidos aislados que codifican las moléculas, vectores, células huésped y métodos para prepararlos.Monospecific and bispecific molecule containing the FN3 domain of EGFR and / or c-Met, isolated nucleotides encoding molecules, vectors, host cells and methods for preparing them are described.
CR20150249A2012-11-212015-05-12
EGFR AND C-MET TYPE III FIBRONECTINE DOMAIN BINDING MODULES
CR20150249A
(en)
Molecule containing the bispecific fibronectin type iii (fn3) domain, where the first domain binds to the epidermal growth factor receptor (egrf) and the second to the hepatocyte growth factor (c-met); fn3 domain; polynucleotide that encodes it; vector; host cell; Method of production; pharmaceutical composition comprising it; and use to treat cancer.